Oral edaravone ameliorates myocardial fibrosis in type 2 diabetic rats by TGF-β1/Smad signaling pathway

被引：0

作者：

Zhang, Xiao-Yan ^{[1
]}

Xu, Yong-xuan ^{[1
]}

Xue, Si-Quan ^{[2
]}

Zeng, Yue-Qin ^{[2
]}

Gu, Juan-Hua ^{[2
]}

Zhou, Xin-Fu ^{[3
,4
]}

Luo, Hai-Yun ^{[1
,5
]}

Pu, Li-Jin ^{[1
,6
]}

机构：

[1] Kunming Med Univ, Affiliated Hosp 1, Fac Basic Med Sci, Dept Cardiol, 296 Xichang Rd, Kunming 650032, Peoples R China

[2] Biomed Engn Res Ctr, Yunnan Key Lab Stem Cells & Regenerat Med, 1168 Chunrong West Rd, Kunming 650500, Peoples R China

[3] Suzhou Auzone Biotech, Suzhou, Peoples R China

[4] Univ South Australia, Hlth & Biomed Innovat, Clin & Hlth Sci, 101 Currie St, Adelaide 5001, Australia

[5] Kunming Med Univ, Fac Basic Med Sci, 1168 Chunrong West Rd, Kunming 650500, Peoples R China

[6] Kunming Med Univ, Affiliated Hosp 1, 296 Xichang Rd, Kunming 650032, Peoples R China

来源：

JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2025年 / 39卷 / 03期

关键词：

TGF-beta 1/Smad signaling pathway; Edaravone; Myocardial fibrosis; Type 2 diabetes mellitus; GROWTH-FACTOR-BETA; OXIDATIVE STRESS; CARDIAC FIBROSIS; CARDIOMYOPATHY; ANTIOXIDANT; AUTOPHAGY; DAMAGE; SCAR;

D O I：

10.1016/j.jdiacomp.2025.108976

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Myocardial fibrosis, characterized by increased reactive oxygen species (ROS), is a key pathological feature of diabetic cardiomyopathy (DCM). Although oral edaravone (EDA) shows therapeutic potential in ameliorating myocardial fibrosis in DCM, the precise mechanisms remain unclear. Transcriptome analysis of myocardial tissues revealed a dramatic up-regulation of the TGF-(31/Smad pathway, which was reversed by oral EDA treatment. In vitro studies showed that oral EDA attenuated myocardial fibrosis by inhibiting the TGF-(31/Smad signaling pathway and its downstream fibrosis key factors, Col3a1 and a-SMA. These findings suggest that oral EDA improves myocardial fibrosis in Type 2 diabetes mellitus (T2DM) by inhibiting the TGF-(31/Smad signaling pathway and holds promise as an effective treatment for myocardial fibrosis in DCM.

引用

页数：11

共 26 条

[21] Novel oral edaravone attenuates diastolic dysfunction of diabetic cardiomyopathy by activating the Nrf2 signaling pathway
Wang, Ling
Zeng, Yue-Qin
Gu, Juan-Hua
Song, Rui
Cang, Peng-Hui
Xu, Yong-Xuan
Shao, Xiao-xia
Pu, Li-Jin
Luo, Hai-Yun
Zhou, Xin-Fu
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 920
[22] Wang Shixiang, 2015, Nan Fang Yi Ke Da Xue Xue Bao, V35, P1591
[23] Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy
Yue, Yiyang
Meng, Ke
Pu, Yuejie
Zhang, Xiaoming
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 133 : 124 - 130
[24] Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor
Zhang, Wei-Wei
Bai, Feng
Wang, Jin
Zheng, Rong-Hua
Yang, Li-Wang
James, Erskine A.
Zhao, Zhi-Qing
[J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 3019 - 3033
[25] Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Yan
Ley, Sylvia H.
Hu, Frank B.
[J]. NATURE REVIEWS ENDOCRINOLOGY, 2018, 14 (02) : 88 - 98
[26] Higenamine attenuates cardiac fibroblast abstract and fibrosis via inhibition of TGF-131/Smad signaling
Zhu, Jin-xing
Ling, Wang
Xue, Chao
Zhou, Zhen
Zhang, Yi-shuai
Yan, Chen
Wu, Mei-ping
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 900

← 1 2 3 →